1
|
Kas MJH, Jongs N, Mennes M, Penninx BWJH, Arango C, van der Wee N, Winter-van Rossum I, Ayuso-Mateos JL, Bilderbeck AC, l'Hostis P, Beckmann CF, Dawson GR, Sommer B, Marston HM. Digital behavioural signatures reveal trans-diagnostic clusters of Schizophrenia and Alzheimer's disease patients. Eur Neuropsychopharmacol 2024; 78:3-12. [PMID: 37864982 DOI: 10.1016/j.euroneuro.2023.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 09/21/2023] [Accepted: 09/25/2023] [Indexed: 10/23/2023]
Abstract
The current neuropsychiatric nosological categories underlie pragmatic treatment choice, regulation and clinical research but does not encompass biological rationale. However, subgroups of patients suffering from schizophrenia or Alzheimer's disease have more in common than the neuropsychiatric nature of their condition, such as the expression of social dysfunction. The PRISM project presents here initial quantitative biological insights allowing the first steps toward a novel trans-diagnostic classification of psychiatric and neurological symptomatology intended to reinvigorate drug discovery in this area. In this study, we applied spectral clustering on digital behavioural endpoints derived from passive smartphone monitoring data in a subgroup of Schizophrenia and Alzheimer's disease patients, as well as age matched healthy controls, as part of the PRISM clinical study. This analysis provided an objective social functioning characterization with three differential clusters that transcended initial diagnostic classification and was shown to be linked to quantitative neurobiological parameters assessed. This emerging quantitative framework will both offer new ways to classify individuals in biologically homogenous clusters irrespective of their initial diagnosis, and also offer insights into the pathophysiological mechanisms underlying these clusters.
Collapse
Affiliation(s)
- Martien J H Kas
- Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands.
| | - Niels Jongs
- Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands
| | | | - Brenda W J H Penninx
- Department of Psychiatry and Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands
| | - Celso Arango
- Donders Institute, Radboud University Medical Centre Nijmegen, the Netherlands
| | - Nic van der Wee
- Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, CIBERSAM, IiSGM, Universidad Complutense, School of Medicine, Madrid, Spain; Department of Psychiatry, Leiden University Medical Center, the Netherlands
| | - Inge Winter-van Rossum
- Leiden Institute for Brain and Cognition/Psychiatric Neuroimaging, Leiden University Medical Center, the Netherlands
| | - Jose Luis Ayuso-Mateos
- Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands; Department of Psychiatry, Universidad Autónoma de Madrid, Madrid, Spain; Centro de Investigación, Biomédica en Red de Salud Mental, CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain; Hospital, Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Madrid, Spain
| | | | | | - Christian F Beckmann
- SBGneuro Ltd, Oxford, United Kingdom; Donders Institute, Radboud University Medical Centre Nijmegen, the Netherlands
| | - Gerard R Dawson
- Boehringer Ingelheim Pharma GmbH & Co KG, CNS Diseases Research, Biberach an der Riss, Germany
| | - Bernd Sommer
- Hospital, Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Madrid, Spain
| | - Hugh M Marston
- Hospital, Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Madrid, Spain; Eli Lilly and Company, Windlesham, United Kingdom
| |
Collapse
|
2
|
Nissen TD, Laursen B, Viardot G, l'Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM. Effects of Vortioxetine and Escitalopram on Electroencephalographic Recordings – A Randomized, Crossover Trial in Healthy Males. Neuroscience 2020; 424:172-181. [DOI: 10.1016/j.neuroscience.2019.09.039] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 09/13/2019] [Accepted: 09/30/2019] [Indexed: 02/06/2023]
|
3
|
Ip CT, Ganz M, Ozenne B, Sluth LB, Gram M, Viardot G, l'Hostis P, Danjou P, Knudsen GM, Christensen SR. Pre-intervention test-retest reliability of EEG and ERP over four recording intervals. Int J Psychophysiol 2018; 134:30-43. [DOI: 10.1016/j.ijpsycho.2018.09.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2018] [Revised: 09/20/2018] [Accepted: 09/21/2018] [Indexed: 10/28/2022]
|
4
|
Pinto R, l'Hostis P, Patat A, Homery MC, Falcão A, Nunes T, Rocha JF, Soares-da-Silva P. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. Clin Pharmacol Drug Dev 2015; 4:454-62. [PMID: 27137718 DOI: 10.1002/cpdd.188] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2014] [Accepted: 02/23/2015] [Indexed: 11/12/2022]
Abstract
Opicapone, a novel third-generation catechol-O-methyltransferase inhibitor for use as adjunctive therapy in levodopa-treated Parkinson's disease patients, was investigated on cardiac repolarization in healthy adult volunteers. This was a single-center, randomized, double-blind, placebo-controlled, open-label active-controlled, 4-period crossover study conducted in 64 subjects. In each period, subjects received a single oral dose of 50 mg opicapone, 800 mg opicapone, placebo, or 400 mg moxifloxacin and 24-hour 12-lead Holter monitoring was performed on day -1 (baseline) and after each single dose. After a single oral administrations of 50 and 800 mg opicapone, opicapone was the major entity in the circulation, with a median tmax of 1.5-2.0 hours. Opicapone was rapidly eliminated, with an elimination half-life of 1-2 hours. There was no clinically relevant effect of 50 and 800 mg opicapone versus placebo on cardiac depolarization or repolarization. All upper bounds of the 1-sided 95% confidence interval (CI) were below 10 milliseconds, confirming that opicapone has no QT-prolonging effect. Moxifloxacin caused an increase in the QTcI, with a lower bound of the 2-sided 95% CI always higher than 5 milliseconds, around the tmax of peak concentration, demonstrating assay sensitivity. In conclusion, administration of opicapone at therapeutic (50 mg) and supratherapeutic (800 mg) doses did not induce a clinically significant prolongation of the QTc interval.
Collapse
Affiliation(s)
- Roberto Pinto
- Dept. Research & Development, BIAL-Portela & Cª-S.A., 4745-457 S. Mamede do Coronado, Portugal.,Dept. Pharmacology & Therapeutics, Faculty of Medicine, University Porto, Porto, Portugal
| | | | | | | | - Amílcar Falcão
- Dept. Pharmacology, Faculty of Pharmacy, University Coimbra, Coimbra, Portugal
| | - Teresa Nunes
- Dept. Research & Development, BIAL-Portela & Cª-S.A., 4745-457 S. Mamede do Coronado, Portugal
| | - José-Francisco Rocha
- Dept. Research & Development, BIAL-Portela & Cª-S.A., 4745-457 S. Mamede do Coronado, Portugal
| | - Patrício Soares-da-Silva
- Dept. Research & Development, BIAL-Portela & Cª-S.A., 4745-457 S. Mamede do Coronado, Portugal.,Dept. Pharmacology & Therapeutics, Faculty of Medicine, University Porto, Porto, Portugal.,MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal
| |
Collapse
|